JP2023532134A5 - - Google Patents
Info
- Publication number
- JP2023532134A5 JP2023532134A5 JP2022581456A JP2022581456A JP2023532134A5 JP 2023532134 A5 JP2023532134 A5 JP 2023532134A5 JP 2022581456 A JP2022581456 A JP 2022581456A JP 2022581456 A JP2022581456 A JP 2022581456A JP 2023532134 A5 JP2023532134 A5 JP 2023532134A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- compound
- pharmaceutically acceptable
- use according
- tautomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063047858P | 2020-07-02 | 2020-07-02 | |
| US63/047,858 | 2020-07-02 | ||
| PCT/US2021/040157 WO2022006439A2 (en) | 2020-07-02 | 2021-07-01 | Compound embodiments for treating retinal degeneration and method embodiments of making and using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023532134A JP2023532134A (ja) | 2023-07-26 |
| JP2023532134A5 true JP2023532134A5 (https=) | 2024-07-04 |
Family
ID=77227100
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022581456A Pending JP2023532134A (ja) | 2020-07-02 | 2021-07-01 | 網膜変性の処置において使用するための環式化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230301984A1 (https=) |
| EP (1) | EP4175636A2 (https=) |
| JP (1) | JP2023532134A (https=) |
| AU (1) | AU2021300425A1 (https=) |
| CA (1) | CA3186586A1 (https=) |
| WO (1) | WO2022006439A2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4705277A1 (en) * | 2023-04-27 | 2026-03-11 | Kiora Pharmaceuticals Pty Ltd | Method of treating vision loss in a human subject with photoreactive compounds |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0489108B1 (en) * | 1989-08-21 | 1996-03-13 | Beth Israel Hospital Association | Use of spiperone derivatives for immunosuppression |
| US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| US5725493A (en) | 1994-12-12 | 1998-03-10 | Avery; Robert Logan | Intravitreal medicine delivery |
| US6299895B1 (en) | 1997-03-24 | 2001-10-09 | Neurotech S.A. | Device and method for treating ophthalmic diseases |
| CA2383499C (en) | 1999-10-21 | 2009-11-24 | Alcon Universal Ltd. | Drug delivery device |
| US6416777B1 (en) | 1999-10-21 | 2002-07-09 | Alcon Universal Ltd. | Ophthalmic drug delivery device |
| CN101534826A (zh) * | 2006-04-14 | 2009-09-16 | 普拉纳生物技术有限公司 | 治疗与年龄相关的黄斑变性（amd）的方法 |
| WO2009035534A2 (en) * | 2007-09-07 | 2009-03-19 | The Cleveland Clinic Foundation | Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif) |
| WO2009089399A2 (en) * | 2008-01-10 | 2009-07-16 | Bausch & Lomb Incorporated | Compositions comprising toll-like receptor or coreceptor antagonists and methods for ocular neuroprotection |
| US10258613B2 (en) * | 2014-02-05 | 2019-04-16 | The Board Of Regents Of The University Of Oklahoma | Compositions for treating retinal degeneration and methods of production and use thereof |
| US11406709B2 (en) * | 2014-09-15 | 2022-08-09 | Trustees Of Boston University | Therapeutic and research application of PDCL3 |
| US10322087B2 (en) * | 2015-03-16 | 2019-06-18 | Mireca Medicines Gmbh | Targeted liposomal delivery of cGMP analogues |
| US20210338770A1 (en) * | 2018-10-15 | 2021-11-04 | Osaka University | Medicament for improving or preventing symptoms relating to retina and/or light reception and method for screening for substance capable of improving or preventing symptoms relating to retina and/or light reception |
-
2021
- 2021-07-01 US US18/014,045 patent/US20230301984A1/en active Pending
- 2021-07-01 CA CA3186586A patent/CA3186586A1/en active Pending
- 2021-07-01 WO PCT/US2021/040157 patent/WO2022006439A2/en not_active Ceased
- 2021-07-01 EP EP21751672.3A patent/EP4175636A2/en active Pending
- 2021-07-01 JP JP2022581456A patent/JP2023532134A/ja active Pending
- 2021-07-01 AU AU2021300425A patent/AU2021300425A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2735229C (en) | Combination therapy for tuberculosis | |
| JP7136886B2 (ja) | Ｈｉｖカプシド阻害剤の固体形態 | |
| US10017459B2 (en) | β-substituted β-amino acids and analogs as chemotherapeutic agents and uses thereof | |
| BR112021005606A2 (pt) | processo de produção de um composto para inibir a atividade de shp2 | |
| JP4220897B2 (ja) | ピペラジン化合物 | |
| JP2013010792A5 (https=) | ||
| WO2019177975A1 (en) | Antibiotics effective for gram-negative pathogens | |
| JP2021535112A5 (https=) | ||
| US20220071970A1 (en) | Quinuclidine-3-one derivatives and their use in cancer treatment | |
| WO2021016333A1 (en) | Aryl sulfonamides as small molecule stat3 inhibitors | |
| JP2010527984A5 (https=) | ||
| JP2010527985A5 (https=) | ||
| CZ33794A3 (en) | Novel pyrazine derivatives, process of their preparation and pharmaceutical preparations in which they are comprised | |
| JOP20240217A1 (ar) | مشتقات الكوينولين كمُعدِّلات للعضو x2 لمستقبل بروتين g مرتبط بـ mas ومنتجات ذات صلة | |
| JP2025061387A (ja) | 複素環式タンパク質キナーゼ阻害剤を含む製剤 | |
| JP2023532134A5 (https=) | ||
| WO2023222122A1 (en) | Solid forms of a compound for treating or preventing hyperuricemia or gout | |
| TWI898321B (zh) | 用於治療或預防高尿酸血症或痛風的化合物的固體晶型 | |
| KR20200138260A (ko) | Ｕｒａｔ－１ 억제제의 신규한 염 형태 | |
| TWI290465B (en) | 9-Anilinoacridine alkylating agents | |
| US10611772B2 (en) | Crystalline form of Ribociclib succinate | |
| BR122025028707A2 (pt) | Métodos para produção de compostos para inibir atividade de shp2 |